- Home
- STRW vs SGHT Comparison
STRW vs SGHT Comparison
Compare STRW & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- SGHT
- Stock Information
- Founded
- STRW 2015
- SGHT 2011
- Country
- STRW United States
- SGHT United States
- Employees
- STRW N/A
- SGHT N/A
- Industry
- STRW Real Estate Investment Trusts
- SGHT Medical Specialities
- Sector
- STRW Real Estate
- SGHT Health Care
- Exchange
- STRW Nasdaq
- SGHT Nasdaq
- Market Cap
- STRW 133.6M
- SGHT 140.1M
- IPO Year
- STRW N/A
- SGHT 2021
- Fundamental
- Price
- STRW $10.15
- SGHT $3.03
- Analyst Decision
- STRW Strong Buy
- SGHT Buy
- Analyst Count
- STRW 4
- SGHT 7
- Target Price
- STRW $13.83
- SGHT $3.92
- AVG Volume (30 Days)
- STRW 45.5K
- SGHT 161.2K
- Earning Date
- STRW 05-09-2025
- SGHT 05-08-2025
- Dividend Yield
- STRW 5.47%
- SGHT N/A
- EPS Growth
- STRW 34.22
- SGHT N/A
- EPS
- STRW 0.58
- SGHT N/A
- Revenue
- STRW $126,557,000.00
- SGHT $78,109,000.00
- Revenue This Year
- STRW $15.21
- SGHT N/A
- Revenue Next Year
- STRW $2.21
- SGHT $11.17
- P/E Ratio
- STRW $17.34
- SGHT N/A
- Revenue Growth
- STRW 22.41
- SGHT N/A
- 52 Week Low
- STRW $8.70
- SGHT $2.03
- 52 Week High
- STRW $12.90
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- STRW 41.28
- SGHT 56.13
- Support Level
- STRW $10.00
- SGHT $2.81
- Resistance Level
- STRW $11.50
- SGHT $3.26
- Average True Range (ATR)
- STRW 0.68
- SGHT 0.24
- MACD
- STRW -0.06
- SGHT -0.01
- Stochastic Oscillator
- STRW 15.09
- SGHT 38.57
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.